Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies

NCT06046391 is registered in ClinicalTrials.gov with Longbio Pharma as lead sponsor.

NCT NCT06046391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies
Lead sponsor
Longbio Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2023
Completion date
August 6, 2024
Enrollment
180 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis